New York, NYNCT07284758Now EnrollingIRB Ready

Multiple Myeloma Clinical Trial in New York, NY

Access cutting-edge multiple myeloma treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.

Sponsored by C4 Therapeutics, Inc.

Quick Self-Assessment

See if you qualify for this New York location

Preparing your pre-screening questions…

Expert Care in New York

Access multiple myeloma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related multiple myeloma treatment provided free

Apply for This New York Location

Check if you qualify for this multiple myeloma clinical trial in New York, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New York

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New York site if eligible
  4. 4Begin participation

About This Multiple Myeloma Study in New York

This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (r/r MM).

Sponsor: C4 Therapeutics, Inc.

Who Can Participate

Inclusion Criteria

Be willing and able to provide signed informed consent for the study.
Age ≥ 18 years at the time of signed consent.
Subjects must have a documented diagnosis of MM and measurable disease at enrollment.
Received at least 3 prior anti-myeloma regimens (for a minimum of 2 or more consecutive cycles) that must have included an immunomodulatory drug (i.e., IKZF 1/3 degrader), a proteasome inhibitor, an anti-CD38 antibody, and a T-cell engager (TCE) or chimeric antigen receptor T-cell (CAR-T) therapy, unless not available per local standard of care.
Subjects need to have adequate organ function.
Toxicities from prior anticancer therapies must have resolved to baseline severity or CTCAE ≤ Grade 1.
Female subjects may not be pregnant or intend to become pregnant, may not breastfeed or intend to breastfeed, or donate ova during their participation in this study until 30 days after the last dose of study treatment.
Male subjects must agree to use a condom when having intercourse with a person of childbearing potential during the Treatment Period and for at least 30 days after the last dose of study treatment.
Male subjects must refrain from donating sperm during the Treatment Period and for 30 days after discontinuation.
Subjects must refrain from donating blood during study treatment and for 30 days after discontinuation.

Exclusion Criteria

Presence of myeloma in the central nervous system (CNS).
Subjects with any of the following:
Systemic light chain amyloidosis
Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, and Skin changes (POEMS) Syndrome
Myelodysplastic syndrome (MDS).
Previously treated with cemsidomide.
Clinically significant impaired cardiac function or cardiac disease.
Thromboembolic event within 3 months prior to enrollment.
Known malignancy other than study indication that has progressed or required treatment within the past 3 years.
Uncontrolled active bacterial, fungal, or viral infection.
Inability or difficulty swallowing tablets. NOTE: Other inclusion/exclusion criteria may apply, per protocol.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT07284758) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Multiple Myeloma Treatment Options in New York, NY

If you're searching for multiple myeloma treatment options in New York, NY, this clinical trial (NCT07284758) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced multiple myeloma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all multiple myeloma clinical trials near you to find additional studies recruiting in your area.

More Multiple Myeloma Trials in New York, NY

See all multiple myeloma clinical trials recruiting in New York — not just this study.

Browse Multiple Myeloma Trials in New York →

Browse More Trials by Condition

Multiple Myeloma TrialsAll Conditions →

Ready to Join in New York?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New York, NY